CytRx Corp Executives

CYTRDelisted Stock  USD 0.18  0.02  12.50%   
CytRx Corp employs about 3 people. The company is managed by 23 executives with a total tenure of roughly 168 years, averaging almost 7.0 years of service per executive, having 0.13 employees per reported executive. Discussion of CytRx Corp's management performance can provide insight into the enterprise performance.
Steven Kriegsman  Chairman
Chairman, CEO and Pres
Douglas Wieland  President
Senior Vice President - Drug Development
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

CytRx Corp Management Team Effectiveness

The company has return on total asset (ROA) of (0.52) % which means that it has lost $0.52 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9189) %, meaning that it created substantial loss on money invested by shareholders. CytRx Corp's management efficiency ratios could be used to measure how well CytRx Corp manages its routine affairs as well as how well it operates its assets and liabilities.

CytRx Corp Workforce Comparison

CytRx Corp is number one stock in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 144,800. CytRx Corp adds roughly 3.0 in number of employees claiming only tiny portion of equities under Health Care industry.

CytRx Corp Notable Stakeholders

A CytRx Corp stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CytRx Corp often face trade-offs trying to please all of them. CytRx Corp's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CytRx Corp's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Steven KriegsmanChairman, CEO and PresProfile
Douglas WielandSenior Vice President - Drug DevelopmentProfile
Daniel LevittExecutive Vice President Chief Medical OfficerProfile
Eric CurtisPresident COOProfile
John CalozCFO, Chief Accounting Officer and TreasurerProfile
Benjamin LevinSr. VP of Legal Affairs, General Counsel and Corporate SecretaryProfile
Louis IgnarroIndependent DirectorProfile
Cheryl CohenDirectorProfile
Joel CaldwellDirectorProfile
Eric SelterIndependent DirectorProfile
Earl BrienDirectorProfile
Anita ChawlaDirectorProfile
Joseph RubinfeldIndependent DirectorProfile
David HaenVP of Bus. Devel. and Investor RelationsProfile
Terri StevensChief OfficerProfile
Felix KratzDrug VPProfile
Michelle CarrollIR Contact OfficerProfile
Cristina NewmanCo SecProfile
Molly PoarchGlobal CommunicationsProfile
Olivia WareChief Commercial OfficerProfile
Shanta ChawlaSenior Executive Officer - Drug DevelopmentProfile
Molly PainterPres OperationsProfile
Stephen SnowdyChief OfficerProfile

About CytRx Corp Management Performance

The success or failure of an entity such as CytRx Corp often depends on how effective the management is. CytRx Corp management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CytRx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CytRx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California. CYTRX CORP operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 3 people.
The data published in CytRx Corp's official financial statements usually reflect CytRx Corp's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of CytRx Corp. For example, before you start analyzing numbers published by CytRx accountants, it's critical to develop an understanding of what CytRx Corp's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of CytRx Corp's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CytRx Corp's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in CytRx Corp's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CytRx Corp. Please utilize our Beneish M Score to check the likelihood of CytRx Corp's management manipulating its earnings.

CytRx Corp Workforce Analysis

Traditionally, organizations such as CytRx Corp use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CytRx Corp within its industry.

CytRx Corp Manpower Efficiency

Return on CytRx Corp Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee4.4M
Net Loss Per Executive572.9K
Working Capital Per Employee13.8M
Working Capital Per Executive1.8M
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Other Consideration for investing in CytRx OTC Stock

If you are still planning to invest in CytRx Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CytRx Corp's history and understand the potential risks before investing.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Bonds Directory
Find actively traded corporate debentures issued by US companies
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Money Managers
Screen money managers from public funds and ETFs managed around the world
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
FinTech Suite
Use AI to screen and filter profitable investment opportunities